The Cost of Access to Mental Health Services in Managed Care

Published data from managed care programs reporting data on cost and access were obtained from a literature review (5,6,7,8). The data covered the years 1992 to 1997. The authors also collected 1993 to 1997 data from proprietary managed care sources and the North Carolina state employee benefit program after the state carved out its mental health benefits in 1992. Analyses are based on a total of 1.25 million persons and 2.75 million person-years.

Claims costs are reported in per-member per-month dollar expenditures by the behavioral health plan. Costs were adjusted for inflation to reflect 1997 dollars, using the medical care consumer price index (9). Neither administrative costs nor patient deductibles and copayments are included.

Access to care was measured using outpatient treated prevalence rates, that is, the proportion of members using outpatient services annually. This measure slightly understates the proportion of individuals receiving any services because a few users may use only inpatient or intermediate-level services. However, most data sources are unable to provide unduplicated counts across treatment settings. Outpatient treated prevalence was chosen as the best estimate of the overall proportion of service users.

The unit of analysis was the managed care plan. To test the hypothesis that claims costs and treated prevalence are directly related, linear regression was used to analyze the data using STATISTIX for Windows (10). The R² represents the proportion of variability in the per-member per-month cost that is explained by the linear relationship between that cost and treated prevalence rates.

A wide range of claims costs and treated prevalence rates was found across plans. Claims costs for mental health services varied sixfold, from $1.97 to $12.04 per member per month (1997 dollars), and treated prevalence varied more than tenfold, from 1.03 to 9.97 percent.

Cost and access data are plotted in Figure 1. A straight line describes the relationship between cost and access well. The regression equation is as follows: treated prevalence (percent) =.9 × per-member per-month cost (dollars) + .25

The slope of the line is .90, and the R² value is .65. Thus each increment of $1 per member per month in spending on claims was associated with a .9 percent increase in the proportion of enrollees receiving specialty mental health treatment. Conversely, each decrement of $1 in spending was associated with a .9 percent decrease in the treated prevalence rate.

These data raise concerns that plans paying lower per-member per-month costs actively contain costs by restricting access to specialty treatment. Before widespread managed care, the Epidemiologic Catchment Area study and the National Comorbidity Survey reported treated prevalence rates of 5.8 to 5.9 percent, with an average of 14 visits per patient per year. Our study shows that it costs about $6 per member per month to reach this level of access. If this is the "appropriate" treated prevalence rate, then claims costs below $6 per member per month should raise concerns about the decline in access, quantity, and quality as a consequence of cost containment. Cost containment strategies that may effectively limit access include benefit design features, such as high copayments and deductibles, stringent authorization-of-care practices, and incentives to reduce referrals to specialty treatment.

Several limitations of the study should be noted. First, we used a convenience sample of managed care plans: those that had published data on cost and access and those that agreed to provide data to NIMH. These plans reflect a wide range of costs but may not be representative of managed care plans overall. However, one might expect that plans voluntarily reporting these data are among the better plans. Second, these plans encompass a range of managed care practices, from loosely managed nonrisk contracts to more tightly managed at-risk arrangements. Third, in some plans, selection factors or different cultural attitudes toward seeking treatment may contribute to variation in demand for services.

A fourth limitation is that our analysis does not account for the lack of independence of multiple observations of the same plan in different years. Finally, mental health treatment in primary care settings was not measured. However, because we studied only plans with behavioral health carve-outs, this limitation is unlikely to be a major source of variability between plans.

It is also important to note that although the proportion of enrollees receiving treatment is a useful indicator of access to care, it does not reflect other aspects of access such as treatment intensity, waiting times for appointments and telephone responses, access to a continuum of services, geographic access, and culturally competent treatment. Nor do populationwide treatment rates reflect differences in access for vulnerable populations, including poor people, members of racial minority groups, those with physical disabilities, and those with severe mental illness.

The direct relationship between claims costs and treated prevalence rates suggests that at low levels of spending, access to care may be compromised. Our results also show that the relationship between cost and access holds throughout a wide range of costs; no upper limit for access was found even at high spending levels, nor was there a spending level below which access leveled off and nonaccess strategies for cost control were the only ones used.

Further studies are needed to examine how barriers to access are enacted and whether they preferentially affect certain patient groups, such as those with severe mental illness. Studies examining treatment intensity and quality in high- and low-cost plans are also needed.

The authors thank Agnes Rupp, Ph.D., and Sam Zuvekas, Ph.D., for helpful discussion and comments.

When this study was conducted, Dr. Weissman was a special expert at the National Institute of Mental Health (NIMH). She is now a psychiatrist at the Mental Illness Research, Education, and Clinical Center at the Bronx Veterans Affairs Medical Center. Dr. Pettigrew is a statistical consultant in the division of services and intervention research at NIMH. Dr. Sotsky formerly was senior science adviser in the office of the associate director for epidemiology and health policy research at NIMH. He is now research professor for psychiatry and public health at the Center for Health Services Research and Policy at George Washington University in Washington, D.C. Dr. Regier formerly was associate director for epidemiology and health policy research at NIMH. He is now executive director of the American Psychiatric Institute for Research and Education. Send correspondence to Dr. Regier at the American Psychiatric Association, 1400 K Street, N.W., Washington, D.C. 20005 (e-mail, [email protected]). This paper was presented at the annual meeting of the American Psychiatric Association held May 15–20, 1999, in Washington, D.C.